The purpose of this study is to determine whether a reduced dose of apixaban is non-inferior to and safer than the full dose of apixaban for the prevention of recurrent venous thromboembolism (VTE) in active cancer patients.
The purpose of this study is to assess the safety and efficacy of pulsed inhaled nitric oxide versus placebo in subjects at risk for pulmonary hypertension associated with pulmonary fibrosis on long term oxygen therapy.
The purpose of this study is determine if a fixed-dose combination of the drugs macitentan and tadalafil is more effective than therapy with macitentan or tadalafil alone to treat pulmonary arterial hypertension.
The purpose of this study is to test the safety and efficacy of an inhaled medication (CSJ117) compared with a placebo for improving lung function in patients with inadequate control of moderate to severe asthma.
The purpose of this study is to determine if dupilumab is effective and safe in decreasing episodes of severe breathing difficulties in patients with allergic bronchopulmonary aspergillosis (ABPA).
The purpose of this study is to determine if BC residents receive, understand and implement public health messages related to wildfire smoke exposures, and to better understand the reach of these messages and identify opportunities for future improvement.
The purpose of this study aims to assess the efficacy and safety of selexipag in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH).
The purpose of this study is to understand how patients with asthma and COPD have been affected by the changes to the health care system as a result of the COVID-19 pandemic.
The purpose of this study is to explore certain aspects of the blood and brain to determine how a person may recover from COVID-19. In addition, this study will examine how the different aspects of COVID-19 may affect how a person thinks or feels.
This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with pulmonary hypertension (PH) who previously participated in controlled clinical studies with bardoxolone methyl.
To demonstrate the effectiveness of riociguat as replacement of phosphodiesterase-5 inhibitors (PDE-5i) therapy in pulmonary arterial hypertension (PAH) patients
Primary Objective:
To evaluate the efficacy of dupilumab compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity and endoscopic nasal polyposis score (NPS) in patients with bilateral nasal polyposis (NP). In addition for Japan, reduction in computed tomography (CT) scan opacification of the sinuses will be also a co-primary objective.
Secondary Objectives:
To evaluate the efficacy of dupilumab in improving total symptoms score (TSS).
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with connective tissue disease-associated pulmonary arterial hypertension to determine the recommended dose range and evaluate the change from baseline in 6-minute walk distance (6MWD) following 24 weeks of study participation.
This is a randomized, double-blind, parallel group, placebo-controlled study designed to evaluate the effect of a fixed 30 mg dose of benralizumab administered subcutaneously every 4 weeks on allergen-induced inflammation in subjects with mild atopic asthma challenged with an inhaled allergen.
The purpose of this study is to evaluate the long-term safety, efficacy and tolerability of dupilumab in patients with asthma who participated in a previous dupilumab asthma study.
This study aims to determine the efficacy and safety of QAW039 (Dose 1 and Dose 2), compared with placebo, when added to GINA steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2015) in each of the groups (patients with severe asthma and high eosinophil counts and all patients with severe asthma).
The objective of this clinical trial is to compare the efficacy and safety of an initial triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral treatment regimen (macitentan, tadalafil, placebo) in newly diagnosed, treatment-naïve patients with pulmonary arterial hypertension.
A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, 12-Week, Phase 2 Study to Evaluate the Effect of Tralokinumab on Airway Inflammation in Adults with Asthma Inadequately Controlled on Inhaled Corticosteroid.
The objectives of this trial are primarily to evaluate the efficacy and safety of BI 655066 as compared to placebo over a 24-week treatment period in severe asthma patients. The primary endpoint is time to first asthma worsening during the planned 24 week treatment period for active vs. placebo treated patients on top of standard of care therapy. Upon demonstration of a meaningful clinical response, another important objective is the identification of biomarkers that can be used to target patients who will likely respond to treatment with BI 655066.
The purpose of this study is to evaluate specific alterations in immune cell mechanisms related to neutrophil function as detected by PI3Kdelta-dependent changes in messenger ribonucleic acid (mRNA) extracted from induced sputum in patients experiencing an exacerbation of COPD, with or without treatment with GSK2269557. The efficacy of treatment with GSK2269557 will also be measured using functional respiratory imaging (FRI) and spirometry. This is a randomised, double-blind, placebo-controlled, parallel-group study.